Xeris Biopharma Holdings, Inc. XERS Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s operating income?
- Xeris Biopharma Holdings, Inc. (XERS) reported operating income of $7.92M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s operating income changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s operating income increased by 356.2% year-over-year, from -$3.09M to $7.92M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s operating income?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s operating income has grown at a -31.8% compound annual growth rate (CAGR), from -$115.16M to $24.9M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.